[3-(trifluoromethoxy)phenyl]boronic acid

• ChemBase ID: 10372
• Molecular Formular: C7H6BF3O3
• Molecular Mass: 205.9269496
• Monoisotopic Mass: 206.03620911
• SMILES: c1cc(cc(c1)B(O)O)OC(F)(F)F
• Canonical SMILES: OB(c1cccc(c1)OC(F)(F)F)O
• InChI: InChI=1S/C7H6BF3O3/c9-7(10,11)14-6-3-1-2-5(4-6)8(12)13/h1-4,12-13H
• InChIKey: UWDFWVLAHRQSKK-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: [3-(trifluoromethoxy)phenyl]boronic acid
• IUPAC Traditional name: 3-(trifluoromethoxy)phenylboronic acid
• Synonyms: 3-Trifluoromethoxybenzeneboronic acid; 3-(Trifluoromethoxy)phenylboronic acid; 3-(Trifluoromethoxy)benzeneboronic acid; 3-(Trifluoromethoxy)phenylboronic acid; 3-(Trifluoromethoxy)benzeneboronic acid; 3-(Trifluoromethoxy)phenylboronic acid; 3-(三氟甲氧基)苯硼酸

Database IDs

• CAS Number: 179113-90-7
• EC Number: 000-000-0
• MDL Number: MFCD01320697
• Beilstein Number: 7531456
• PubChem SID: 24873478; 160973679
• PubChem CID: 2734385

CALCULATED PROPERTIES

• Acid pKa: 8.627324
• H Acceptors: 3
• H Donor: 2
• LogD (pH = 5.5): 3.3219779
• LogD (pH = 7.4): 3.2974346
• Log P: 3.3223
• Molar Refractivity: 33.6738 cm^3
• Polarizability: 15.58238 Å^3
• Polar Surface Area: 49.69 Å^2
• Rotatable Bonds: 3
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Melting Point: 84-89 °C(lit.); ca 80°C; ca 80°C

Safety Information

• Storage Warning: Irritant
• European Hazard Symbols: Irritant (Xi)
• German water hazard class: 3
• Risk Statements: 36/37/38
• Safety Statements: 26-37
• TSCA Listed: false; 否
• GHS Pictograms: GHS07
• GHS Hazard statements: H315-H319-H335
• GHS Precautionary statements: P261-P305+P351+P338-P302+P352-P321-P405-P501A
• Personal Protective Equipment: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter

Product Information

• Purity: 97%; 98%
• Linear Formula: CF3OC6H4B(OH)2

DETAILS

Sigma Aldrich - 510122

Other Notes
Contains varying amounts of anhydride
Packaging
5 g in glass bottle
Application
Precursor commonly used in the synthesis of biologically active compounds including:
• Multisubstituted purines for use as P2X7 antagonists in the treatment of pain1
• Heteroaryl substituted tetrahydropyrroloijquinolinone derivatives as aldosterone synthase inhibitors2
• Fluorohydroquinolineethanol as a CETP inhibitor3
• Biaryl amides with muscarinic acetylcholine receptor subtype M1 agonist activity4
• C2-aryl pyrrolobenzodiasepine antitumor agents5
• Piperazine-bisamide for obesity treatments6